OIA response: Fingolimod data

Response to a request for data on fingolimod and other medicines.

26 November 2019

[name and contact details redacted]

Dear [name redacted]

REQUEST FOR INFORMATION

Thank you for your request dated 2 November 2019 under the Official Information Act 1982 (OIA) for information on drug usage.  You asked for

the usage (in both retail and hospital pharmacy channels) of the drugs below in the past three years:

  • Fingolimod 0.5mg capsules
  • Levodopa+Benserazide tablets 100mg + 25mg
  • Levodopa+Benserazide tablets 200 mg + 50mg

PHARMAC does not collect information on drug usage, data is only collected for medicines dispensed. We have provided this information in the table below.

Chemical and presentation

Year

Number of units dispensed in community

Number of units purchased by hospitals

Total

Fingolimod Cap 0.5 mg

   

2016

61,553

336

61,889

2017

134,781

308

135,089

2018

142,647

167

142,814

2019

71,179

225

71,404

Levodopa with benserazide, Cap 200 mg with benserazide 50 mg

   

2016

100,869

2,600

103,469

2017

206,084

3,196

209,280

2018

222,008

4,716

226,724

2019

110,834

2,176

113,010

Levodopa with benserazide, Cap 100 mg with benserazide 25 mg

   

2016

681,596

13,500

695,096

2017

1,433,526

24,444

1,457,970

2018

1,575,855

21,008

1,596,863

2019

844,035

13,432

857,467

We trust that this information answers your queries.  We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website.  Please get in touch with us if you have any questions about this.

Yours sincerely

Alison Hill
Director, Engagement and Implementation